{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:20:37Z","timestamp":1793067637482,"version":"4.5.0"},"reference-count":204,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["LJKMZ20221207"],"award-info":[{"award-number":["LJKMZ20221207"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001862","name":"the Swedish Research Council","doi-asserted-by":"crossref","award":["2023-02216"],"award-info":[{"award-number":["2023-02216"]}],"id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008444","name":"Parkinsonfonden","doi-asserted-by":"publisher","award":["1494\/2023, 1663\/2025"],"award-info":[{"award-number":["1494\/2023, 1663\/2025"]}],"id":[{"id":"10.13039\/100008444","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000942","name":"The Brain Foundation","doi-asserted-by":"crossref","award":["FO2023-0397, FO2025-0296"],"award-info":[{"award-number":["FO2023-0397, FO2025-0296"]}],"id":[{"id":"10.13039\/501100000942","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82371273, 82361138574, 31800898, 81430025, and U1801681"],"award-info":[{"award-number":["82371273, 82361138574, 31800898, 81430025, and U1801681"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012131","name":"department of Science and Technology of Liaoning Province","doi-asserted-by":"crossref","award":["2024JH6\/100800008"],"award-info":[{"award-number":["2024JH6\/100800008"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neurodegenerative diseases are increasingly linked to systemic metabolic dysfunction, with brain insulin resistance (BIR) positioned as a central mediator. Yet translating this insight into effective therapies has proven remarkably difficult. This review argues that BIR-driven neurodegeneration should be interpreted at two distinct but interconnected levels: cell-type-specific disruption of brain homeostasis by BIR, and the direct, mechanistic role of BIR in driving the proteinopathies that define Alzheimer\u2019s and Parkinson\u2019s diseases. We first show how BIR produces distinct functional deficits across neurons, astrocytes, microglia, and oligodendrocytes, impairing synaptic plasticity, metabolic coupling, immunometabolic homeostasis, and myelination, resulting in a cellular milieu that favors proteinopathy. We then map molecular pathways through which BIR directly distrubs the metabolism of amyloid-\u03b2, tau, and \u03b1-synuclein. We further examine how islet amyloid polypeptide cross-seeds cerebral amyloid pathology, suggesting a direct molecular interaction between the peripheral drivers of BIR and protein aggregation. In this framework, BIR functions not as a passive risk factor, but as an active, upstream driver of proteostatic collapse. Cellular dysfunction combined with proteostatic failure, defines the therapeutic target space. We evaluate interventions accordingly, distinguishing those that primarily restore cellular function from those that enhance protein clearance, and those that achieve both. For each strategy, we assess the translational evidence, critically appraising the barriers that have limited their clinical success, including patient heterogeneity, narrow therapeutic windows, and inadequate central nervous system delivery. By integrating cell-type-specific biology with proteostatic mechanisms and a clinically oriented therapeutic framework, this review aims to provide a foundation for multi-target strategies that address the BIR\u2013neurodegeneration axis at its mechanistic roots.<\/jats:p>","DOI":"10.1186\/s40035-026-00573-1","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:47:37Z","timestamp":1785739657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Brain insulin resistance as a driver of proteinopathy in neurodegeneration: from cell-type-specific mechanisms to targeted therapeutics"],"prefix":"10.1186","volume":"15","author":[{"given":"Man","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Heng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Zhe","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"4","key":"573_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson 3rd","year":"2023","unstructured":"Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693\u2013714.","journal-title":"Cell"},{"issue":"7","key":"573_CR2","doi-asserted-by":"publisher","first-page":"a28035","DOI":"10.1101\/cshperspect.a028035","volume":"9","author":"BN Dugger","year":"2017","unstructured":"Dugger BN, Dickson DW. Pathology of neurodegenerative disease. Cold Spring Harb Perspect Biol. 2017;9(7):a28035.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7266","key":"573_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/461895a","volume":"461","author":"L Mucke","year":"2009","unstructured":"Mucke L. Neuroscience: Alzheimer\u2019s disease. Nature. 2009;461(7266):895\u20137.","journal-title":"Nature"},{"issue":"9996","key":"573_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"issue":"6","key":"573_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70363","volume":"21","author":"VZ Lau","year":"2025","unstructured":"Lau VZ, Awogbindin IO, Frenkel D, Whitehead SN, Tremblay M. A hypothesis explaining Alzheimer\u2019s disease, Parkinson\u2019s disease, and dementia with Lewy bodies overlap. Alzheimers Dement. 2025;21(6):e70363.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"573_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1210\/en.2009-0838","volume":"151","author":"CM Mayer","year":"2010","unstructured":"Mayer CM, Belsham DD. Central insulin signaling is attenuated by long-term insulin exposure via insulin receptor substrate-1 serine phosphorylation, proteasomal degradation, and lysosomal insulin receptor degradation. Endocrinology. 2010;151(1):75\u201384.","journal-title":"Endocrinology"},{"issue":"1","key":"573_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/13872877251326107","volume":"105","author":"S Jeong","year":"2025","unstructured":"Jeong S, Lin L, Leone AP, Hsu YH. Type 2 diabetes and late-onset Alzheimer\u2019s disease and related dementia: a longitudinal cohort study integrating polygenic risk score. J Alzheimers Dis. 2025;105(1):107\u201319.","journal-title":"J Alzheimers Dis"},{"key":"573_CR8","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.73138","volume":"11","author":"B Antal","year":"2022","unstructured":"Antal B, Mcmahon LP, Sultan SF, Lithen A, Wexler DJ, Dickerson B, et al. Type 2 diabetes mellitus accelerates brain aging and cognitive decline: complementary findings from UK Biobank and meta-analyses. Elife. 2022;11:e73138.","journal-title":"Elife"},{"key":"573_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100944","volume":"55","author":"M Xue","year":"2019","unstructured":"Xue M, Xu W, Ou YN, Cao XP, Tan MS, Tan L, et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev. 2019;55:100944.","journal-title":"Ageing Res Rev"},{"issue":"2","key":"573_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2337\/dc15-1588","volume":"39","author":"S Chatterjee","year":"2016","unstructured":"Chatterjee S, Peters SA, Woodward M, Mejia Arango S, Batty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39(2):300\u20137.","journal-title":"Diabetes Care"},{"issue":"2","key":"573_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/JPD-181305","volume":"8","author":"E Hogg","year":"2018","unstructured":"Hogg E, Athreya K, Basile C, Tan EE, Kaminski J, Tagliati M. High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson\u2019s disease. J Parkinsons Dis. 2018;8(2):259\u201365.","journal-title":"J Parkinsons Dis"},{"key":"573_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101727","volume":"81","author":"M Faizan","year":"2022","unstructured":"Faizan M, Sarkar A, Singh MP. Type 2 diabetes mellitus augments Parkinson\u2019s disease risk or the other way around: Facts, challenges and future possibilities. Ageing Res Rev. 2022;81:101727.","journal-title":"Ageing Res Rev"},{"issue":"2","key":"573_CR13","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","volume":"91","author":"E De Pablo-Fernandez","year":"2018","unstructured":"De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology. 2018;91(2):e139\u201342.","journal-title":"Neurology"},{"issue":"5","key":"573_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00702-025-02882-7","volume":"132","author":"O Stockmann","year":"2025","unstructured":"Stockmann O, Ye L, Greten S, Chemodanow D, Wegner F, Klietz M. Impact of diabetes mellitus type two on incidence and progression of Parkinson\u2019s disease: a systematic review of longitudinal patient cohorts. J Neural Transm. 2025;132(5):627\u201335.","journal-title":"J Neural Transm"},{"issue":"3","key":"573_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1474-4422(04)00681-7","volume":"3","author":"S Craft","year":"2004","unstructured":"Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3(3):169\u201378.","journal-title":"Lancet Neurol"},{"key":"573_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564641","volume":"8","author":"SY Chou","year":"2020","unstructured":"Chou SY, Chan L, Chung CC, Chiu JY, Hsieh YC, Hong CT. Altered insulin receptor substrate 1 phosphorylation in blood neuron-derived extracellular vesicles from patients with Parkinson\u2019s Disease. Front Cell Dev Biol. 2020;8:564641.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"573_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/brain\/awac309","volume":"146","author":"M Leclerc","year":"2023","unstructured":"Leclerc M, Bourassa P, Tremblay C, Caron V, Sug\u00e8re C, Emond V, et al. Cerebrovascular insulin receptors are defective in Alzheimer\u2019s disease. Brain. 2023;146(1):75\u201390.","journal-title":"Brain"},{"key":"573_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.547175","volume":"14","author":"M Shaughness","year":"2020","unstructured":"Shaughness M, Acs D, Brabazon F, Hockenbury N, Byrnes KR. Role of insulin in neurotrauma and neurodegeneration: a review. Front Neurosci. 2020;14:547175.","journal-title":"Front Neurosci"},{"issue":"13","key":"573_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131728","volume":"12","author":"MA Ansari","year":"2023","unstructured":"Ansari MA, Al-Jarallah A, Babiker FA. Impaired insulin signaling alters mediators of hippocampal synaptic dynamics\/plasticity: a possible mechanism of hyperglycemia-induced cognitive impairment. Cells. 2023;12(13):1728.","journal-title":"Cells"},{"issue":"2","key":"573_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10787-023-01187-z","volume":"31","author":"V Kakoty","year":"2023","unstructured":"Kakoty V, Kc S, Kumari S, Yang CH, Dubey SK, Sahebkar A, et al. Brain insulin resistance linked Alzheimer\u2019s and Parkinson\u2019s disease pathology: an undying implication of epigenetic and autophagy modulation. Inflammopharmacology. 2023;31(2):699\u2013716.","journal-title":"Inflammopharmacology"},{"issue":"8","key":"573_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41574-021-00498-x","volume":"17","author":"T Scherer","year":"2021","unstructured":"Scherer T, Sakamoto K, Buettner C. Brain insulin signalling in metabolic homeostasis and disease. Nat Rev Endocrinol. 2021;17(8):468\u201383.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"573_CR22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","volume":"19","author":"D Kellar","year":"2020","unstructured":"Kellar D, Craft S. Brain insulin resistance in Alzheimer\u2019s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19(9):758\u201366.","journal-title":"Lancet Neurol"},{"issue":"8","key":"573_CR23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.tem.2025.06.006","volume":"36","author":"M Sun","year":"2025","unstructured":"Sun M, Mi W. Microglial insulin resistance drives neurodegeneration. Trends Endocrinol Metab. 2025;36(8):696\u20138.","journal-title":"Trends Endocrinol Metab"},{"issue":"13","key":"573_CR24","doi-asserted-by":"publisher","first-page":"e1150","DOI":"10.1212\/WNL.0000000000005214","volume":"90","author":"LL Ekblad","year":"2018","unstructured":"Ekblad LL, Johansson J, Helin S, Viitanen M, Laine H, Puukka P, et al. Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation. Neurology. 2018;90(13):e1150\u20137.","journal-title":"Neurology"},{"issue":"4","key":"573_CR25","first-page":"1688","volume":"15","author":"EM Rhea","year":"2024","unstructured":"Rhea EM, Leclerc M, Yassine HN, Capuano AW, Tong H, Petyuk VA, et al. State of the science on brain insulin resistance and cognitive decline due to Alzheimer\u2019s disease. Aging Dis. 2024;15(4):1688\u2013725.","journal-title":"Aging Dis"},{"key":"573_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-biochem-052521-033250","volume":"92","author":"E Choi","year":"2023","unstructured":"Choi E, Bai XC. The activation mechanism of the insulin receptor: a structural perspective. Annu Rev Biochem. 2023;92:247\u201372.","journal-title":"Annu Rev Biochem"},{"issue":"19","key":"573_CR27","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1016\/j.devcel.2025.05.008","volume":"60","author":"Y Cormerais","year":"2025","unstructured":"Cormerais Y, Lapp SC, Kalafut KC, Ciss\u00e9 MY, Shin J, Stefadu B, et al. AKT-mediated phosphorylation of TSC2 controls stimulus- and tissue-specific mTORC1 signaling and organ growth. Dev Cell. 2025;60(19):2544-2557.e7.","journal-title":"Dev Cell"},{"issue":"5","key":"573_CR28","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1038\/cddis.2013.148","volume":"4","author":"P Sanphui","year":"2013","unstructured":"Sanphui P, Biswas SC. FoxO3a is activated and executes neuron death via Bim in response to \u03b2-amyloid. Cell Death Dis. 2013;4(5):e625.","journal-title":"Cell Death Dis"},{"issue":"5","key":"573_CR29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.tins.2022.03.001","volume":"45","author":"W Chen","year":"2022","unstructured":"Chen W, Cai W, Hoover B, Kahn CR. Insulin action in the brain: cell types, circuits, and diseases. Trends Neurosci. 2022;45(5):384\u2013400.","journal-title":"Trends Neurosci"},{"key":"573_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.brainres.2009.08.005","volume":"1296","author":"CA Grillo","year":"2009","unstructured":"Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res. 2009;1296:35\u201345.","journal-title":"Brain Res"},{"key":"573_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00668","volume":"14","author":"HN Frazier","year":"2020","unstructured":"Frazier HN, Ghoweri AO, Anderson KL, Lin RL, Popa GJ, Mendenhall MD, et al. Elevating insulin signaling using a constitutively active insulin receptor increases glucose metabolism and expression of GLUT3 in hippocampal neurons. Front Neurosci. 2020;14:668.","journal-title":"Front Neurosci"},{"issue":"3","key":"573_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/MNM.0000000000001511","volume":"43","author":"Y Chen","year":"2022","unstructured":"Chen Y, Qiu C, Yu W, Shao X, Zhou M, Wang Y. The relationship between brain glucose metabolism and insulin resistance in subjects with normal cognition - a study based on 18F-FDG PET. Nucl Med Commun. 2022;43(3):275\u201383.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"573_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/archneurol.2010.225","volume":"68","author":"LD Baker","year":"2011","unstructured":"Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68(1):51\u20137.","journal-title":"Arch Neurol"},{"key":"573_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuroscience.2019.05.033","volume":"411","author":"F Zhao","year":"2019","unstructured":"Zhao F, Siu JJ, Huang W, Askwith C, Cao L. Insulin modulates excitatory synaptic transmission and synaptic plasticity in the mouse hippocampus. Neuroscience. 2019;411:237\u201354.","journal-title":"Neuroscience"},{"key":"573_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2026.1716291","volume":"18","author":"S Tang","year":"2026","unstructured":"Tang S, Liao Y, Yang M, Yue R. Brain insulin resistance: a key pathological hub linking metabolic and neuropsychiatric comorbidities. Front Aging Neurosci. 2026;18:1716291.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"573_CR36","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","volume":"478","author":"K Ramasubbu","year":"2023","unstructured":"Ramasubbu K, Devi Rajeswari V. Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol Cell Biochem. 2023;478(6):1307\u201324.","journal-title":"Mol Cell Biochem"},{"issue":"22","key":"573_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252211955","volume":"25","author":"M Kciuk","year":"2024","unstructured":"Kciuk M, Kruczkowska W, Ga\u0142\u0119ziewska J, Wanke K, Ka\u0142uzi\u0144ska-Ko\u0142at \u017b, Aleksandrowicz M, et al. Alzheimer\u2019s disease as type 3 diabetes: understanding the link and implications. Int J Mol Sci. 2024;25(22):11955.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"573_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1161\/01.ATV.20.2.402","volume":"20","author":"C Hermann","year":"2000","unstructured":"Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20(2):402\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"573_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104707","volume":"135","author":"A Akhtar","year":"2020","unstructured":"Akhtar A, Sah SP. Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer\u2019s disease. Neurochem Int. 2020;135:104707.","journal-title":"Neurochem Int"},{"issue":"15","key":"573_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20153702","volume":"20","author":"IO Zakharova","year":"2019","unstructured":"Zakharova IO, Sokolova TV, Bayunova LV, Zorina II, Rychkova MP, Shpakov AO, et al. The protective effect of insulin on rat cortical neurons in oxidative stress and its dependence on the modulation of Akt, GSK-3beta, ERK1\/2, and AMPK activities. Int J Mol Sci. 2019;20(15):3702.","journal-title":"Int J Mol Sci"},{"key":"573_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118653","volume":"335","author":"BD Akamba Ambamba","year":"2024","unstructured":"Akamba Ambamba BD, Ella FA, Ngassa Ngoumen DJ, Dibacto Kemadjou RE, Agwe NI, Mbappe FE, et al. Tannins-enriched fraction of TeMac\u2122 protects against aluminum chloride induced Alzheimer\u2019s disease-like pathology by modulating aberrant insulin resistance and alleviating oxidative stress in diabetic rats. J Ethnopharmacol. 2024;335:118653.","journal-title":"J Ethnopharmacol"},{"issue":"14","key":"573_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146581","volume":"26","author":"C B\u00f6r\u00f6czky","year":"2025","unstructured":"B\u00f6r\u00f6czky C, Pasztern\u00e1k A, Laufer R, Tarn\u00f3czi K, Sikur N, Bagam\u00e9ry F, et al. Neuroinflammation based neurodegenerative &lt;changed&gt;in vitro&lt;\/changed&gt; model of SH-SY5Y cells-differential effects on oxidative stress and insulin resistance relevant to Alzheimer\u2019s pathology. Int J Mol Sci. 2025;26(14):6581.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"573_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13220","volume":"19","author":"HN Frazier","year":"2020","unstructured":"Frazier HN, Anderson KL, Ghoweri AO, Lin RL, Hawkinson TR, Popa GJ, et al. Molecular elevation of insulin receptor signaling improves memory recall in aged Fischer 344 rats. Aging Cell. 2020;19(10):e13220.","journal-title":"Aging Cell"},{"issue":"1","key":"573_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12035-011-8229-6","volume":"46","author":"HB Schi\u00f6th","year":"2012","unstructured":"Schi\u00f6th HB, Craft S, Brooks SJ, Frey WH 2nd, Benedict C. Brain insulin signaling and Alzheimer\u2019s disease: current evidence and future directions. Mol Neurobiol. 2012;46(1):4\u201310.","journal-title":"Mol Neurobiol"},{"issue":"6","key":"573_CR45","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/jmri.28358","volume":"56","author":"Y Cui","year":"2022","unstructured":"Cui Y, Tang TY, Lu CQ, Ju S. Insulin resistance and cognitive impairment: evidence from neuroimaging. J Magn Reson Imaging. 2022;56(6):1621\u201349.","journal-title":"J Magn Reson Imaging"},{"key":"573_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.826193","volume":"16","author":"A Ni","year":"2022","unstructured":"Ni A, Ernst C. Evidence that substantia nigra pars compacta dopaminergic neurons are selectively vulnerable to oxidative stress because they are highly metabolically active. Front Cell Neurosci. 2022;16:826193.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"573_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0306-4522(89)90036-5","volume":"31","author":"J Unger","year":"1989","unstructured":"Unger J, Mcneill TH, Moxley RT 3rd, White M, Moss A, Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience. 1989;31(1):143\u201357.","journal-title":"Neuroscience"},{"key":"573_CR48","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","volume":"145\u2013146","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T. Insulin resistance and Parkinson\u2019s disease: a new target for disease modification? Prog Neurobiol. 2016;145\u2013146:98\u2013120.","journal-title":"Prog Neurobiol"},{"issue":"3","key":"573_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JAD-2005-8304","volume":"8","author":"EJ Rivera","year":"2005","unstructured":"Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, De La Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer\u2019s disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005;8(3):247\u201368.","journal-title":"J Alzheimers Dis"},{"issue":"42","key":"573_CR50","doi-asserted-by":"publisher","first-page":"eadp1115","DOI":"10.1126\/sciadv.adp1115","volume":"10","author":"CG Ardanaz","year":"2024","unstructured":"Ardanaz CG, De La Cruz A, Minhas PS, Hern\u00e1ndez-Mart\u00edn N, Pozo M, Valdecantos MP, et al. Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis. Sci Adv. 2024;10(42):eadp1115.","journal-title":"Sci Adv"},{"issue":"4","key":"573_CR51","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.cell.2016.07.028","volume":"166","author":"C Garc\u00eda-C\u00e1ceres","year":"2016","unstructured":"Garc\u00eda-C\u00e1ceres C, Quarta C, Varela L, Gao Y, Gruber T, Legutko B, et al. Astrocytic insulin signaling couples brain glucose uptake with nutrient availability. Cell. 2016;166(4):867\u201380.","journal-title":"Cell"},{"issue":"8","key":"573_CR52","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.cmet.2021.07.006","volume":"33","author":"G Bonvento","year":"2021","unstructured":"Bonvento G, Bola\u00f1os JP. Astrocyte-neuron metabolic cooperation shapes brain activity. Cell Metab. 2021;33(8):1546\u201364.","journal-title":"Cell Metab"},{"key":"573_CR53","unstructured":"Bentivegna M, Pomilio C, Bellotto M, P\u00e9rez NG, Rossi SP, Gregosa A, et al. Amyloid beta regulates astrocytic glucose metabolism and insulin signaling in experimental models of Alzheimer\u2019s Disease. Aging Dis. 2025."},{"key":"573_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuint.2016.03.014","volume":"98","author":"MB Robinson","year":"2016","unstructured":"Robinson MB, Jackson JG. Astroglial glutamate transporters coordinate excitatory signaling and brain energetics. Neurochem Int. 2016;98:56\u201371.","journal-title":"Neurochem Int"},{"issue":"2","key":"573_CR55","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/jnc.14634","volume":"148","author":"ER Hascup","year":"2019","unstructured":"Hascup ER, Broderick SO, Russell MK, Fang Y, Bartke A, Boger HA, et al. Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in A\u03b2PP\/PS1 mice. J Neurochem. 2019;148(2):219\u201337.","journal-title":"J Neurochem"},{"issue":"5","key":"573_CR56","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1007\/s12035-024-04644-0","volume":"62","author":"S Das","year":"2025","unstructured":"Das S, Mccloskey K, Nepal B, Kortagere S. EAAT2 activation regulates glutamate excitotoxicity and reduces impulsivity in a rodent model of Parkinson\u2019s Disease. Mol Neurobiol. 2025;62(5):5787\u2013803.","journal-title":"Mol Neurobiol"},{"key":"573_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exger.2016.11.004","volume":"94","author":"S Tarantini","year":"2017","unstructured":"Tarantini S, Tran CHT, Gordon GR, Ungvari Z, Csiszar A. Impaired neurovascular coupling in aging and Alzheimer\u2019s disease: contribution of astrocyte dysfunction and endothelial impairment to cognitive decline. Exp Gerontol. 2017;94:52\u20138.","journal-title":"Exp Gerontol"},{"issue":"5","key":"573_CR58","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s11357-021-00405-2","volume":"43","author":"S Tarantini","year":"2021","unstructured":"Tarantini S, Ny\u00fal-T\u00f3th \u00c1, Yabluchanskiy A, Csipo T, Mukli P, Balasubramanian P, et al. Endothelial deficiency of insulin-like growth factor-1 receptor (IGF1R) impairs neurovascular coupling responses in mice, mimicking aspects of the brain aging phenotype. Geroscience. 2021;43(5):2387\u201394.","journal-title":"Geroscience"},{"issue":"29","key":"573_CR59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204527119","volume":"119","author":"AM Fernandez","year":"2022","unstructured":"Fernandez AM, Martinez-Rachadell L, Navarrete M, Pose-Utrilla J, Davila JC, Pignatelli J, et al. Insulin regulates neurovascular coupling through astrocytes. Proc Natl Acad Sci U S A. 2022;119(29):e2204527119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"573_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.976340","volume":"14","author":"A Canna","year":"2022","unstructured":"Canna A, Esposito F, Tedeschi G, Trojsi F, Passaniti C, Di Meo I, et al. Neurovascular coupling in patients with type 2 diabetes mellitus. Front Aging Neurosci. 2022;14:976340.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"573_CR61","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41583-022-00558-9","volume":"23","author":"FG De Felice","year":"2022","unstructured":"De Felice FG, Gon\u00e7alves RA, Ferreira ST. Impaired insulin signalling and allostatic load in Alzheimer disease. Nat Rev Neurosci. 2022;23(4):215\u201330.","journal-title":"Nat Rev Neurosci"},{"issue":"16","key":"573_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/cells12162019","volume":"12","author":"S Raut","year":"2023","unstructured":"Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L. Hypometabolism, Alzheimer\u2019s disease, and possible therapeutic targets: an overview. Cells. 2023;12(16):2019.","journal-title":"Cells"},{"issue":"11","key":"573_CR63","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1159\/000524059","volume":"112","author":"YV Doust","year":"2022","unstructured":"Doust YV, Sumargo N, Ziebell JM, Premilovac D. Insulin resistance in the brain: evidence supporting a role for inflammation, reactive microglia, and the impact of biological sex. Neuroendocrinology. 2022;112(11):1027\u201338.","journal-title":"Neuroendocrinology"},{"issue":"23","key":"573_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252313169","volume":"25","author":"R Darwish","year":"2024","unstructured":"Darwish R, Alcibahy Y, Bucheeri S, Albishtawi A, Tama M, Shetty J, et al. The role of hypothalamic microglia in the onset of insulin resistance and type 2 diabetes: a neuro-immune perspective. Int J Mol Sci. 2024;25(23):13169.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"573_CR65","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.cmet.2025.06.005","volume":"37","author":"E Barone","year":"2025","unstructured":"Barone E, Butterfield DA. Insulin signaling in microglia: a metabolic switch controlling neuroinflammation and amyloid pathology in Alzheimer\u2019s disease. Cell Metab. 2025;37(8):1630\u20132.","journal-title":"Cell Metab"},{"issue":"10","key":"573_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305614","volume":"11","author":"S Yang","year":"2024","unstructured":"Yang S, Qin C, Chen M, Chu YH, Tang Y, Zhou LQ, et al. TREM2-IGF1 mediated glucometabolic enhancement underlies microglial neuroprotective properties during ischemic stroke. Adv Sci (Weinh). 2024;11(10):e2305614.","journal-title":"Adv Sci (Weinh)"},{"issue":"21","key":"573_CR67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2501527122","volume":"122","author":"W Chen","year":"2025","unstructured":"Chen W, Liu X, Mu\u00f1oz VR, Kahn CR. Loss of insulin signaling in microglia impairs cellular uptake of A\u03b2 and neuroinflammatory response exacerbating AD-like neuropathology. Proc Natl Acad Sci U S A. 2025;122(21):e2501527122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"573_CR68","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.1007\/s12035-025-04775-y","volume":"62","author":"M Fang","year":"2025","unstructured":"Fang M, Zhou Y, He K, Lu Y, Tao F, Huang H. Glucose metabolic reprogramming in microglia: implications for neurodegenerative diseases and targeted therapy. Mol Neurobiol. 2025;62(7):8204\u201321.","journal-title":"Mol Neurobiol"},{"key":"573_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00365","volume":"9","author":"JL Labandeira-Garcia","year":"2017","unstructured":"Labandeira-Garcia JL, Costa-Besada MA, Labandeira CM, Villar-Cheda B, Rodr\u00edguez-Perez AI. Insulin-like growth factor-1 and neuroinflammation. Front Aging Neurosci. 2017;9:365.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"573_CR70","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/brain\/awx044","volume":"140","author":"F Bassil","year":"2017","unstructured":"Bassil F, Canron MH, Vital A, Bezard E, Li Y, Greig NH, et al. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain. 2017;140(5):1420\u201336.","journal-title":"Brain"},{"key":"573_CR71","unstructured":"De La Monte SM, Grammas P. Insulin resistance and oligodendrocyte\/microvascular endothelial cell dysfunction as mediators of white matter degeneration in Alzheimer\u2019s Disease. In: Wisniewski T, editor. Alzheimer\u2019s disease. Brisbane (AU): The Authors; 2019."},{"issue":"9","key":"573_CR72","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/oby.22558","volume":"27","author":"JP O\u2019Grady","year":"2019","unstructured":"O\u2019Grady JP, Dean DC 3rd, Yang KL, Canda CM, Hoscheidt SM, Starks EJ, et al. Elevated insulin and insulin resistance are associated with altered myelin in cognitively unimpaired middle-aged adults. Obesity (Silver Spring). 2019;27(9):1464\u201371.","journal-title":"Obesity (Silver Spring)"},{"issue":"15","key":"573_CR73","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1523\/JNEUROSCI.3442-16.2017","volume":"37","author":"CC Liu","year":"2017","unstructured":"Liu CC, Hu J, Zhao N, Wang J, Wang N, Cirrito JR, et al. Astrocytic LRP1 mediates brain A\u03b2 clearance and impacts amyloid deposition. J Neurosci. 2017;37(15):4023\u201331.","journal-title":"J Neurosci"},{"issue":"1","key":"573_CR74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1172\/JCI81108","volume":"126","author":"SE Storck","year":"2016","unstructured":"Storck SE, Meister S, Nahrath J, Mei\u00dfner JN, Schubert N, Di Spiezio A, et al. Endothelial LRP1 transports amyloid-\u03b2(1-42) across the blood-brain barrier. J Clin Invest. 2016;126(1):123\u201336.","journal-title":"J Clin Invest"},{"issue":"6","key":"573_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101609","volume":"5","author":"C Baltira","year":"2024","unstructured":"Baltira C, Aronica E, Elmquist WF, Langer O, L\u00f6scher W, Sarkaria JN, et al. The impact of ATP-binding cassette transporters in the diseased brain: context matters. Cell Rep Med. 2024;5(6):101609.","journal-title":"Cell Rep Med"},{"key":"573_CR76","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbi.2018.07.017","volume":"73","author":"SE Storck","year":"2018","unstructured":"Storck SE, Hartz AMS, Bernard J, Wolf A, Kachlmeier A, Mahringer A, et al. The concerted amyloid-beta clearance of LRP1 and ABCB1\/P-gp across the blood-brain barrier is linked by PICALM. Brain Behav Immun. 2018;73:21\u201333.","journal-title":"Brain Behav Immun"},{"key":"573_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116643","volume":"231","author":"W Li","year":"2025","unstructured":"Li W, Chen C, Xu B, Chen J, Yang M, Gao L, et al. The LDL Receptor-related protein 1: mechanisms and roles in promoting A\u03b2 efflux transporter in Alzheimer\u2019s disease. Biochem Pharmacol. 2025;231:116643.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"573_CR78","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2174\/1567205013666160314151012","volume":"13","author":"W Wang","year":"2016","unstructured":"Wang W, Bodles-Brakhop AM, Barger SW. A role for P-glycoprotein in clearance of Alzheimer amyloid \u03b2-peptide from the brain. Curr Alzheimer Res. 2016;13(6):615\u201320.","journal-title":"Curr Alzheimer Res"},{"issue":"6\u20137","key":"573_CR79","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.neuropharm.2009.03.001","volume":"56","author":"H Hong","year":"2009","unstructured":"Hong H, Liu LP, Liao JM, Wang TS, Ye FY, Wu J, et al. Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice. Neuropharmacology. 2009;56(6\u20137):1054\u20139.","journal-title":"Neuropharmacology"},{"issue":"8","key":"573_CR80","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.bcp.2008.01.004","volume":"75","author":"H Liu","year":"2008","unstructured":"Liu H, Liu X, Jia L, Liu Y, Yang H, Wang G, et al. Insulin therapy restores impaired function and expression of P-glycoprotein in blood-brain barrier of experimental diabetes. Biochem Pharmacol. 2008;75(8):1649\u201358.","journal-title":"Biochem Pharmacol"},{"issue":"14","key":"573_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146693","volume":"26","author":"M Cerasuolo","year":"2025","unstructured":"Cerasuolo M, Auriemma MC, Di Meo I, Lenti C, Papa M, Paolisso G, et al. Understanding the insulin-degrading enzyme: a new look at Alzheimer\u2019s disease and A\u03b2 plaque management. Int J Mol Sci. 2025;26(14):6693.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"573_CR82","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-017-0152-5","volume":"12","author":"E Portelius","year":"2017","unstructured":"Portelius E, Mattsson N, Pannee J, Zetterberg H, Gissl\u00e9n M, Vanderstichele H, et al. Ex vivo (18)O-labeling mass spectrometry identifies a peripheral amyloid \u03b2 clearance pathway. Mol Neurodegener. 2017;12(1):18.","journal-title":"Mol Neurodegener"},{"key":"573_CR83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.neuroscience.2018.06.018","volume":"385","author":"N Yamamoto","year":"2018","unstructured":"Yamamoto N, Ishikuro R, Tanida M, Suzuki K, Ikeda-Matsuo Y, Sobue K. Insulin-signaling pathway regulates the degradation of amyloid \u03b2-protein via astrocytes. Neuroscience. 2018;385:227\u201336.","journal-title":"Neuroscience"},{"issue":"1","key":"573_CR84","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.tips.2017.10.008","volume":"39","author":"IV Kurochkin","year":"2018","unstructured":"Kurochkin IV, Guarnera E, Berezovsky IN. Insulin-degrading enzyme in the fight against Alzheimer\u2019s disease. Trends Pharmacol Sci. 2018;39(1):49\u201358.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"573_CR85","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1172\/JCI64516","volume":"123","author":"PT Ly","year":"2013","unstructured":"Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, et al. Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest. 2013;123(1):224\u201335.","journal-title":"J Clin Invest"},{"issue":"3","key":"573_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/md19030152","volume":"19","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Lee N, Youn K, Jo MR, Kim HR, Lee DS, et al. Dieckol ameliorates A\u03b2 production via PI3K\/Akt\/GSK-3\u03b2 regulated APP processing in SweAPP N2a cell. Mar Drugs. 2021;19(3):152.","journal-title":"Mar Drugs"},{"issue":"6","key":"573_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061388","volume":"9","author":"T Domoto","year":"2020","unstructured":"Domoto T, Uehara M, Bolidong D, Minamoto T. Glycogen synthase kinase 3\u03b2 in cancer biology and treatment. Cells. 2020;9(6):1388.","journal-title":"Cells"},{"issue":"1","key":"573_CR88","first-page":"001","volume":"1","author":"DW Maixner","year":"2013","unstructured":"Maixner DW, Weng HR. The role of glycogen synthase kinase 3 beta in neuroinflammation and pain. J Pharm Pharmacol (Los Angel). 2013;1(1):001.","journal-title":"J Pharm Pharmacol (Los Angel)"},{"key":"573_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156168","volume":"135","author":"J Huang","year":"2024","unstructured":"Huang J, Xu Z, Yu C, Liu L, Ji L, Qiu P, et al. The volatile oil of Acorus tatarinowii Schott ameliorates Alzheimer\u2019s disease through improving insulin resistance via activating the PI3K\/AKT pathway. Phytomedicine. 2024;135:156168.","journal-title":"Phytomedicine"},{"key":"573_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00801","volume":"13","author":"S Chatterjee","year":"2019","unstructured":"Chatterjee S, Ambegaokar SS, Jackson GR, Mudher A. Insulin-mediated changes in tau hyperphosphorylation and autophagy in a Drosophila model of tauopathy and neuroblastoma cells. Front Neurosci. 2019;13:801.","journal-title":"Front Neurosci"},{"issue":"1","key":"573_CR91","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2990.2006.00795.x","volume":"33","author":"K Leroy","year":"2007","unstructured":"Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer\u2019s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol. 2007;33(1):43\u201355.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"Suppl 1","key":"573_CR92","first-page":"S141","volume":"33","author":"F Hernandez","year":"2013","unstructured":"Hernandez F, Lucas JJ, Avila J. GSK3 and tau: two convergence points in Alzheimer\u2019s disease. J Alzheimers Dis. 2013;33(Suppl 1):S141\u20134.","journal-title":"J Alzheimers Dis"},{"key":"573_CR93","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS\u20131 dysregulation, and cognitive decline. J Clin Invest. 2012;122:1316\u201338.","journal-title":"J Clin Invest"},{"issue":"41","key":"573_CR94","doi-asserted-by":"publisher","first-page":"E3945","DOI":"10.1073\/pnas.1309991110","volume":"110","author":"A Oueslati","year":"2013","unstructured":"Oueslati A, Schneider BL, Aebischer P, Lashuel HA. Polo-like kinase 2 regulates selective autophagic \u03b1-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A. 2013;110(41):E3945\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"573_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030740","volume":"9","author":"CT Hong","year":"2020","unstructured":"Hong CT, Chen KY, Wang W, Chiu JY, Wu D, Chao TY, et al. Insulin resistance promotes Parkinson\u2019s disease through aberrant expression of \u03b1-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells. 2020;9(3):740.","journal-title":"Cells"},{"issue":"5","key":"573_CR96","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1074\/jbc.C800206200","volume":"284","author":"KJ Inglis","year":"2009","unstructured":"Inglis KJ, Chereau D, Brigham EF, Chiou SS, Sch\u00f6bel S, Frigon NL, et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem. 2009;284(5):2598\u2013602.","journal-title":"J Biol Chem"},{"key":"573_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587229","volume":"11","author":"YW Chang","year":"2020","unstructured":"Chang YW, Hung LC, Chen YC, Wang WH, Lin CY, Tzeng HH, et al. Insulin reduces inflammation by regulating the activation of the NLRP3 inflammasome. Front Immunol. 2020;11:587229.","journal-title":"Front Immunol"},{"issue":"13","key":"573_CR98","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1111\/jcmm.17784","volume":"27","author":"M Alrouji","year":"2023","unstructured":"Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Jabir MS, et al. NF-\u03baB\/NLRP3 inflammasome axis and risk of Parkinson\u2019s disease in Type 2 diabetes mellitus: a narrative review and new perspective. J Cell Mol Med. 2023;27(13):1775\u201389.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"573_CR99","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/jnnp-2016-314601","volume":"88","author":"E De Pablo-Fern\u00e1ndez","year":"2017","unstructured":"De Pablo-Fern\u00e1ndez E, Breen DP, Bouloux PM, Barker RA, Foltynie T, Warner TT. Neuroendocrine abnormalities in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2017;88(2):176\u201385.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"573_CR100","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40035-025-00467-8","volume":"14","author":"L Chen","year":"2025","unstructured":"Chen L, Wang C, Qin L, Zhang H. Parkinson\u2019s disease and glucose metabolism impairment. Transl Neurodegener. 2025;14(1):10.","journal-title":"Transl Neurodegener"},{"key":"573_CR101","doi-asserted-by":"publisher","first-page":"2798269","DOI":"10.1155\/2016\/2798269","volume":"2016","author":"R Akter","year":"2016","unstructured":"Akter R, Cao P, Noor H, Ridgway Z, Tu LH, Wang H, et al. Islet amyloid polypeptide: structure, function, and pathophysiology. J Diabetes Res. 2016;2016:2798269.","journal-title":"J Diabetes Res"},{"issue":"2","key":"573_CR102","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/jcp.30600","volume":"237","author":"C Marmentini","year":"2022","unstructured":"Marmentini C, Branco RCS, Boschero AC, Kurauti MA. Islet amyloid toxicity: from genesis to counteracting mechanisms. J Cell Physiol. 2022;237(2):1119\u201342.","journal-title":"J Cell Physiol"},{"issue":"1","key":"573_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00518-y","volume":"17","author":"G Zhang","year":"2022","unstructured":"Zhang G, Meng L, Wang Z, Peng Q, Chen G, Xiong J, et al. Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer\u2019s disease. Mol Neurodegener. 2022;17(1):12.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"573_CR104","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12917","volume":"49","author":"S Libard","year":"2023","unstructured":"Libard S, Alafuzoff I. Is islet amyloid polypeptide indeed expressed in the human brain. Neuropathol Appl Neurobiol. 2023;49(4):e12917.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"573_CR105","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3233\/JAD-215339","volume":"87","author":"GL Dharmaraj","year":"2022","unstructured":"Dharmaraj GL, Arigo FD, Young KA, Martins R, Mancera RL, Bharadwaj P. Novel amylin analogues reduce amyloid-\u03b2 cross-seeding aggregation and neurotoxicity. J Alzheimers Dis. 2022;87(1):373\u201390.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"573_CR106","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1074\/jbc.M117.806109","volume":"293","author":"P Krotee","year":"2018","unstructured":"Krotee P, Griner SL, Sawaya MR, Cascio D, Rodriguez JA, Shi D, et al. Common fibrillar spines of amyloid-\u03b2 and human islet amyloid polypeptide revealed by microelectron diffraction and structure-based inhibitors. J Biol Chem. 2018;293(8):2888\u2013902.","journal-title":"J Biol Chem"},{"issue":"11","key":"573_CR107","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1021\/acschemneuro.9b00516","volume":"10","author":"S Arya","year":"2019","unstructured":"Arya S, Claud SL, Cantrell KL, Bowers MT. Catalytic prion-like cross-talk between a key Alzheimer\u2019s disease tau-fragment R3 and the type 2 diabetes peptide IAPP. ACS Chem Neurosci. 2019;10(11):4757\u201365.","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"573_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29030740","volume":"29","author":"N Santos","year":"2024","unstructured":"Santos N, Segura L, Lewis A, Pham T, Cheng K-O. Multiscale modeling of macromolecular interactions between tau-amylin oligomers and asymmetric lipid nanodomains that link Alzheimer\u2019s and diabetic diseases. Molecules. 2024;29(3):740.","journal-title":"Molecules"},{"issue":"1","key":"573_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77409-z","volume":"10","author":"M Mucibabic","year":"2020","unstructured":"Mucibabic M, Steneberg P, Lidh E, Straseviciene J, Ziolkowska A, Dahl U, et al. \u03b1-Synuclein promotes IAPP fibril formation in vitro and \u03b2-cell amyloid formation in vivo in mice. Sci Rep. 2020;10(1):20438.","journal-title":"Sci Rep"},{"issue":"44","key":"573_CR110","doi-asserted-by":"publisher","first-page":"12473","DOI":"10.1073\/pnas.1610371113","volume":"113","author":"I Horvath","year":"2016","unstructured":"Horvath I, Wittung-Stafshede P. Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson\u2019s disease. Proc Natl Acad Sci U S A. 2016;113(44):12473\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"573_CR111","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.7150\/thno.112396","volume":"15","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Lai M, Shu B, Wang B, Wang D, Liu H, et al. Unraveling \u03b1-synuclein and amylin co-aggregation: pathological insights and biomarker development for Parkinson\u2019s disease. Theranostics. 2025;15(15):7409\u201324.","journal-title":"Theranostics"},{"key":"573_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2023.102462","volume":"226","author":"L Meng","year":"2023","unstructured":"Meng L, Li Y, Liu C, Zhang G, Chen J, Xiong M, et al. Islet amyloid polypeptide triggers \u03b1-synuclein pathology in Parkinson\u2019s disease. Prog Neurobiol. 2023;226:102462.","journal-title":"Prog Neurobiol"},{"issue":"4","key":"573_CR113","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/ana.25570","volume":"86","author":"I Martinez-Valbuena","year":"2019","unstructured":"Martinez-Valbuena I, Valenti-Azcarate R, Amat-Villegas I, Riverol M, Marcilla I, De Andrea CE, et al. Amylin as a potential link between type 2 diabetes and alzheimer disease. Ann Neurol. 2019;86(4):539\u201351.","journal-title":"Ann Neurol"},{"issue":"6","key":"573_CR114","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00401-018-1832-0","volume":"135","author":"I Martinez-Valbuena","year":"2018","unstructured":"Martinez-Valbuena I, Amat-Villegas I, Valenti-Azcarate R, Carmona-Abellan MDM, Marcilla I, Tu\u00f1on MT, et al. Interaction of amyloidogenic proteins in pancreatic \u03b2 cells from subjects with synucleinopathies. Acta Neuropathol. 2018;135(6):877\u201386.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"573_CR115","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12130","volume":"7","author":"H Ly","year":"2021","unstructured":"Ly H, Verma N, Sharma S, Kotiya D, Despa S, Abner EL, et al. The association of circulating amylin with \u03b2-amyloid in familial Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2021;7(1):e12130.","journal-title":"Alzheimers Dement (N Y)"},{"key":"573_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113490","volume":"334","author":"HC Chen","year":"2020","unstructured":"Chen HC, Cao JX, Cai YT, Du HL, Xi XX, Sun J, et al. Interaction of human IAPP and A\u03b2(1)-(42) aggravated the AD-related pathology and impaired the cognition in mice. Exp Neurol. 2020;334:113490.","journal-title":"Exp Neurol"},{"key":"573_CR117","unstructured":"Caiyan L, Feng Y. The deposition and cross-seeding of islet amyloid polypeptide and phosphorylated \u03b1-synuclein in gut, myocardium, and brain of cynomolgus monkeys with spontaneous type 2 diabetes mellitus. In: Proc SPIE. 2025; 13296: 132960F."},{"key":"573_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00063","volume":"14","author":"Y Sun","year":"2020","unstructured":"Sun Y, Guo C, Yuan L, Li W, Wang ZY, Yue F, et al. Cynomolgus monkeys with spontaneous type-2-diabetes-mellitus-like pathology develop alpha-synuclein alterations reminiscent of prodromal Parkinson\u2019s disease and related diseases. Front Neurosci. 2020;14:63.","journal-title":"Front Neurosci"},{"issue":"12","key":"573_CR119","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.1096\/fj.201700431R","volume":"31","author":"N Wijesekara","year":"2017","unstructured":"Wijesekara N, Ahrens R, Sabale M, Wu L, Ha K, Verdile G, et al. Amyloid-\u03b2 and islet amyloid pathologies link Alzheimer\u2019s disease and type 2 diabetes in a transgenic model. FASEB J. 2017;31(12):5409\u201318.","journal-title":"FASEB J"},{"issue":"3","key":"573_CR120","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/path.5674","volume":"254","author":"N Wijesekara","year":"2021","unstructured":"Wijesekara N, Gon\u00e7alves RA, Ahrens R, Ha K, De Felice FG, Fraser PE. Combination of human tau and islet amyloid polypeptide exacerbates metabolic dysfunction in transgenic mice. J Pathol. 2021;254(3):244\u201353.","journal-title":"J Pathol"},{"issue":"Pt 2","key":"573_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.148663","volume":"332","author":"CYJ Wong","year":"2025","unstructured":"Wong CYJ, Baldelli A, Tietz O, Leite E, Ong HX, Traini D. Intranasal delivery of insulin: an update on status quo and challenges for diabetes treatment. Int J Biol Macromol. 2025;332(Pt 2):148663.","journal-title":"Int J Biol Macromol"},{"issue":"Pt B","key":"573_CR122","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neuropharm.2017.11.037","volume":"136","author":"CD Chapman","year":"2018","unstructured":"Chapman CD, Schi\u00f6th HB, Grillo CA, Benedict C. Intranasal insulin in Alzheimer\u2019s disease: food for thought. Neuropharmacology. 2018;136(Pt B):196\u2013201.","journal-title":"Neuropharmacology"},{"issue":"1","key":"573_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39191-5","volume":"9","author":"JJ Lochhead","year":"2019","unstructured":"Lochhead JJ, Kellohen KL, Ronaldson PT, Davis TP. Distribution of insulin in trigeminal nerve and brain after intranasal administration. Sci Rep. 2019;9(1):2621.","journal-title":"Sci Rep"},{"key":"573_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00629","volume":"13","author":"S Gabbouj","year":"2019","unstructured":"Gabbouj S, Ryh\u00e4nen S, Marttinen M, Wittrahm R, Takalo M, Kemppainen S, et al. Altered insulin signaling in Alzheimer\u2019s disease brain\u2014special emphasis on PI3K-Akt pathway. Front Neurosci. 2019;13:629.","journal-title":"Front Neurosci"},{"issue":"1","key":"573_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05165-3","volume":"12","author":"D Kellar","year":"2022","unstructured":"Kellar D, Register T, Lockhart SN, Aisen P, Raman R, Rissman RA, et al. Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer\u2019s disease: a randomized trial. Sci Rep. 2022;12(1):1346.","journal-title":"Sci Rep"},{"issue":"24","key":"573_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415811","volume":"23","author":"A Woodfield","year":"2022","unstructured":"Woodfield A, Gonzales T, Helmerhorst E, Laws S, Newsholme P, Porter T, et al. Current insights on the use of insulin and the potential use of insulin mimetics in targeting insulin signalling in Alzheimer\u2019s disease. Int J Mol Sci. 2022;23(24):15811.","journal-title":"Int J Mol Sci"},{"key":"573_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2021.113370","volume":"234","author":"JM Erichsen","year":"2021","unstructured":"Erichsen JM, Calva CB, Reagan LP, Fadel JR. Intranasal insulin and orexins to treat age-related cognitive decline. Physiol Behav. 2021;234:113370.","journal-title":"Physiol Behav"},{"issue":"6","key":"573_CR128","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.bbamcr.2008.02.016","volume":"1783","author":"AI Duarte","year":"2008","unstructured":"Duarte AI, Santos P, Oliveira CR, Santos MS, Rego AC. Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression. Biochim Biophys Acta. 2008;1783(6):994\u20131002.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"573_CR129","doi-asserted-by":"publisher","first-page":"6507","DOI":"10.1007\/s12035-016-0169-8","volume":"54","author":"N Rajasekar","year":"2017","unstructured":"Rajasekar N, Nath C, Hanif K, Shukla R. Intranasal insulin administration ameliorates streptozotocin (ICV)-induced insulin receptor dysfunction, neuroinflammation, amyloidogenesis, and memory impairment in rats. Mol Neurobiol. 2017;54(8):6507\u201322.","journal-title":"Mol Neurobiol"},{"issue":"5","key":"573_CR130","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/acel.12498","volume":"15","author":"YF Mao","year":"2016","unstructured":"Mao YF, Guo Z, Zheng T, Jiang Y, Yan Y, Yin X, et al. Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe\/PS1dE9 mice. Aging Cell. 2016;15(5):893\u2013902.","journal-title":"Aging Cell"},{"key":"573_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/srep45971","volume":"7","author":"Z Guo","year":"2017","unstructured":"Guo Z, Chen Y, Mao YF, Zheng T, Jiang Y, Yan Y, et al. Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer\u2019s rat model. Sci Rep. 2017;7:45971.","journal-title":"Sci Rep"},{"key":"573_CR132","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.expneurol.2014.06.004","volume":"261","author":"Y Chen","year":"2014","unstructured":"Chen Y, Zhao Y, Dai CL, Liang Z, Run X, Iqbal K, et al. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces A\u03b2 level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol. 2014;261:610\u20139.","journal-title":"Exp Neurol"},{"key":"573_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2025.138337","volume":"865","author":"YF Mao","year":"2025","unstructured":"Mao YF, Chen L, Liu JY, Guo ZY, Lu PL, Chen YX. Intranasal insulin administration shows limited tau-targeted effects in early-stage APP\/PS1 Alzheimer\u2019s mice. Neurosci Lett. 2025;865:138337.","journal-title":"Neurosci Lett"},{"key":"573_CR134","doi-asserted-by":"publisher","first-page":"20240191","DOI":"10.1590\/1980-5764-dn-2024-0191","volume":"19","author":"LJ De Oliveira Andrade","year":"2025","unstructured":"De Oliveira Andrade LJ, Matos G, Matos De Oliveira L. Intranasal insulin in Alzheimer disease (diabetes in situ?): a systematic review and meta-analysis. Dement Neuropsychol. 2025;19:20240191.","journal-title":"Dement Neuropsychol"},{"issue":"9","key":"573_CR135","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","volume":"77","author":"S Craft","year":"2020","unstructured":"Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77(9):1099\u2013109.","journal-title":"JAMA Neurol"},{"issue":"7","key":"573_CR136","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/dom.13279","volume":"20","author":"V Schmid","year":"2018","unstructured":"Schmid V, Kullmann S, Gfr\u00f6rer W, Hund V, Hallschmid M, Lipp HP, et al. Safety of intranasal human insulin: a review. Diabetes Obes Metab. 2018;20(7):1563\u201377.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"573_CR137","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3233\/JAD-122308","volume":"35","author":"A Claxton","year":"2013","unstructured":"Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer\u2019s disease. J Alzheimers Dis. 2013;35(4):789\u201397.","journal-title":"J Alzheimers Dis"},{"key":"573_CR138","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2017.11.040","volume":"270","author":"P Picone","year":"2018","unstructured":"Picone P, Sabatino MA, Ditta LA, Amato A, San Biagio PL, Mul\u00e8 F, et al. Nose-to-brain delivery of insulin enhanced by a nanogel carrier. J Control Release. 2018;270:23\u201336.","journal-title":"J Control Release"},{"key":"573_CR139","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.biomaterials.2015.11.057","volume":"80","author":"P Picone","year":"2016","unstructured":"Picone P, Ditta LA, Sabatino MA, Militello V, San Biagio PL, Di Giacinto ML, et al. Ionizing radiation-engineered nanogels as insulin nanocarriers for the development of a new strategy for the treatment of Alzheimer\u2019s disease. Biomaterials. 2016;80:179\u201394.","journal-title":"Biomaterials"},{"issue":"1","key":"573_CR140","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s43856-026-01471-3","volume":"6","author":"A Georgiou","year":"2026","unstructured":"Georgiou A, Zanos P, Onisiforou A. Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer\u2019s disease via dual actions. Commun Med (Lond). 2026;6(1):196.","journal-title":"Commun Med (Lond)"},{"key":"573_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1415740","volume":"15","author":"W Cui","year":"2024","unstructured":"Cui W, Lv C, Geng P, Fu M, Zhou W, Xiong M, et al. Novel targets and therapies of metformin in dementia: old drug, new insights. Front Pharmacol. 2024;15:1415740.","journal-title":"Front Pharmacol"},{"key":"573_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114193","volume":"180","author":"N Katila","year":"2020","unstructured":"Katila N, Bhurtel S, Park PH, Hong JT, Choi DY. Activation of AMPK\/aPKC\u03b6\/CREB pathway by metformin is associated with upregulation of GDNF and dopamine. Biochem Pharmacol. 2020;180:114193.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"573_CR143","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13195-025-01772-0","volume":"17","author":"A Mary","year":"2025","unstructured":"Mary A, Barale S, Eysert F, Valverde A, Lacas-Gervais S, Bauer C, et al. Hampered AMPK-ULK1 cascade in Alzheimer\u2019s disease (AD) instigates mitochondria dysfunctions and AD-related alterations which are alleviated by metformin. Alzheimers Res Ther. 2025;17(1):127.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"573_CR144","doi-asserted-by":"publisher","first-page":"9545","DOI":"10.1007\/s12035-025-04844-2","volume":"62","author":"SS Alves","year":"2025","unstructured":"Alves SS, Rossi L, De Oliveira JAC, Servilha-Menezes G, Grigorio-De-Sant\u2019Ana M, Mazzei RF, et al. Metformin improves spatial memory and reduces seizure severity in a rat model of epilepsy and Alzheimer\u2019s disease comorbidity via PI3K\/Akt signaling pathway. Mol Neurobiol. 2025;62(8):9545\u201372.","journal-title":"Mol Neurobiol"},{"key":"573_CR145","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","volume":"69","author":"Z Ou","year":"2018","unstructured":"Ou Z, Kong X, Sun X, He X, Zhang L, Gong Z, et al. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice. Brain Behav Immun. 2018;69:351\u201363.","journal-title":"Brain Behav Immun"},{"key":"573_CR146","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuropharm.2017.08.015","volume":"125","author":"N Katila","year":"2017","unstructured":"Katila N, Bhurtel S, Shadfar S, Srivastav S, Neupane S, Ojha U, et al. Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology. 2017;125:396\u2013407.","journal-title":"Neuropharmacology"},{"issue":"9","key":"573_CR147","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw047","volume":"19","author":"M Lu","year":"2016","unstructured":"Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G. Metformin prevents dopaminergic neuron death in MPTP\/P-induced mouse model of Parkinson\u2019s disease via autophagy and mitochondrial ROS clearance. Int J Neuropsychopharmacol. 2016;19(9):pyw047.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"573_CR148","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2337\/dc24-1414","volume":"48","author":"M Sun","year":"2025","unstructured":"Sun M, Wang X, Lu Z, Yang Y, Lv S, Miao M, et al. Metformin use and risk of delirium in older adults with type 2 diabetes. Diabetes Care. 2025;48(7):1172\u20139.","journal-title":"Diabetes Care"},{"issue":"12","key":"573_CR149","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1002\/alz.13349","volume":"19","author":"B Zheng","year":"2023","unstructured":"Zheng B, Su B, Ahmadi-Abhari S, Kapogiannis D, Tzoulaki I, Riboli E, et al. Dementia risk in patients with type 2 diabetes: comparing metformin with no pharmacological treatment. Alzheimers Dement. 2023;19(12):5681\u20139.","journal-title":"Alzheimers Dement"},{"key":"573_CR150","doi-asserted-by":"crossref","unstructured":"Nair KS, Pataky M, Ruegsegger G, Jo HJ, Klaus K, Sevits K, et al. Improvement in insulin sensitivity prevents decline in glucose uptake, functional connectivity, and volume in the insulin resistant human brain. Res Sq. 2025.","DOI":"10.21203\/rs.3.rs-7462946\/v1"},{"issue":"3","key":"573_CR151","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3233\/JAD-190123","volume":"71","author":"AJT Yang","year":"2019","unstructured":"Yang AJT, Frendo-Cumbo S, Macpherson REK. Resveratrol and metformin recover prefrontal cortex AMPK activation in diet-induced obese mice but reduce BDNF and synaptophysin protein content. J Alzheimers Dis. 2019;71(3):945\u201356.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"573_CR152","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cmet.2016.12.009","volume":"25","author":"JJ Howell","year":"2017","unstructured":"Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, et al. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25(2):463\u201371.","journal-title":"Cell Metab"},{"issue":"11","key":"573_CR153","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.70283","volume":"169","author":"NI Nicol","year":"2025","unstructured":"Nicol NI, Ma T. Activation of the AMPK signaling and brain function: a friend or foe? J Neurochem. 2025;169(11):e70283.","journal-title":"J Neurochem"},{"issue":"3","key":"573_CR154","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41419-019-1464-x","volume":"10","author":"M Domise","year":"2019","unstructured":"Domise M, Sauv\u00e9 F, Didier S, Caillerez R, B\u00e9gard S, Carrier S, et al. Neuronal AMP-activated protein kinase hyper-activation induces synaptic loss by an autophagy-mediated process. Cell Death Dis. 2019;10(3):221.","journal-title":"Cell Death Dis"},{"issue":"10","key":"573_CR155","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1089\/ars.2010.3544","volume":"14","author":"P Weisov\u00e1","year":"2011","unstructured":"Weisov\u00e1 P, D\u00e1vila D, Tuffy LP, Ward MW, Concannon CG, Prehn JH. Role of 5\u2019-adenosine monophosphate-activated protein kinase in cell survival and death responses in neurons. Antioxid Redox Signal. 2011;14(10):1863\u201376.","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"573_CR156","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3233\/JPD-171296","volume":"8","author":"DW Curry","year":"2018","unstructured":"Curry DW, Stutz B, Andrews ZB, Elsworth JD. Targeting AMPK signaling as a neuroprotective strategy in Parkinson\u2019s disease. J Parkinsons Dis. 2018;8(2):161\u201381.","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"573_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040486","volume":"18","author":"W Kruczkowska","year":"2025","unstructured":"Kruczkowska W, Ga\u0142\u0119ziewska J, Buczek P, P\u0142uciennik E, Kciuk M, \u015aliwi\u0144ska A. Overview of metformin and neurodegeneration: a comprehensive review. Pharmaceuticals (Basel). 2025;18(4):486.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"573_CR158","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2174\/138161206780574579","volume":"12","author":"A Bernardo","year":"2006","unstructured":"Bernardo A, Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des. 2006;12(1):93\u2013109.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"573_CR159","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2174\/1570159X16666180828100002","volume":"17","author":"MA Khan","year":"2019","unstructured":"Khan MA, Alam Q, Haque A, Ashafaq M, Khan MJ, Ashraf GM, et al. Current progress on peroxisome proliferator-activated receptor gamma agonist as an emerging therapeutic approach for the treatment of Alzheimer\u2019s disease: an update. Curr Neuropharmacol. 2019;17(3):232\u201346.","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"573_CR160","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/brain\/awaf462","volume":"149","author":"J Zu","year":"2026","unstructured":"Zu J, Li C, Cui M, Liu X, Pan Z, Li X, et al. Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer\u2019s disease model. Brain. 2026;149(2):668\u201379.","journal-title":"Brain"},{"key":"573_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00178","volume":"11","author":"Q Quan","year":"2019","unstructured":"Quan Q, Qian Y, Li X, Li M. Pioglitazone reduces \u03b2 amyloid levels via inhibition of PPAR\u03b3 phosphorylation in a neuronal model of Alzheimer\u2019s disease. Front Aging Neurosci. 2019;11:178.","journal-title":"Front Aging Neurosci"},{"key":"573_CR162","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70431","author":"A Santiago-Balmaseda","year":"2026","unstructured":"Santiago-Balmaseda A, Villegas-Rojas MM, P\u00e9rez-Segura I, Espino-Cambr\u00f3n M, Martinez-Fong D, Soto-Rojas LO. Schedule-dependent neuroprotection by pioglitazone in a novel model of \u03b1-synucleinopathy in rats: integrated behavioural and histological outcomes. Br J Pharmacol.\u00a02026;183(15):4227-4245.","journal-title":"Br J Pharmacol"},{"key":"573_CR163","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.2147\/DDDT.S367229","volume":"16","author":"A Alhowail","year":"2022","unstructured":"Alhowail A, Alsikhan R, Alsaud M, Aldubayan M, Rabbani SI. Protective effects of pioglitazone on cognitive impairment and the underlying mechanisms: a review of literature. Drug Des Devel Ther. 2022;16:2919\u201331.","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"573_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100306","volume":"7","author":"CH Tseng","year":"2018","unstructured":"Tseng CH. Pioglitazone reduces dementia risk in patients with type 2 diabetes mellitus: a retrospective cohort analysis. J Clin Med. 2018;7(10):306.","journal-title":"J Clin Med"},{"issue":"7","key":"573_CR165","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1474-4422(21)00043-0","volume":"20","author":"DK Burns","year":"2021","unstructured":"Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O\u2019Neil J, et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer\u2019s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(7):537\u201347.","journal-title":"Lancet Neurol"},{"issue":"7","key":"573_CR166","volume":"12","author":"ML Nelson","year":"2023","unstructured":"Nelson ML, Pfeifer JA, Hickey JP, Collins AE, Kalisch BE. Exploring rosiglitazone\u2019s potential to treat Alzheimer\u2019s disease through the modulation of brain-derived neurotrophic factor. Biology (Basel). 2023;12(7):1042.","journal-title":"Biology (Basel)"},{"issue":"5","key":"573_CR167","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/mp300570z","volume":"10","author":"AK Deo","year":"2013","unstructured":"Deo AK, Theil FP, Nicolas JM. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Mol Pharm. 2013;10(5):1581\u201395.","journal-title":"Mol Pharm"},{"key":"573_CR168","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l7078","volume":"368","author":"JD Wallach","year":"2020","unstructured":"Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, et al. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ. 2020;368:l7078.","journal-title":"BMJ"},{"key":"573_CR169","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1541","volume":"352","author":"M Tuccori","year":"2016","unstructured":"Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541.","journal-title":"BMJ"},{"issue":"1","key":"573_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13300-012-0001-z","volume":"3","author":"J Govindan","year":"2012","unstructured":"Govindan J, Evans M. Pioglitazone in clinical practice: where are we now? Diabetes Ther. 2012;3(1):1\u20138.","journal-title":"Diabetes Ther"},{"issue":"Pt B","key":"573_CR171","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","volume":"136","author":"C H\u00f6lscher","year":"2018","unstructured":"H\u00f6lscher C. Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models. Neuropharmacology. 2018;136(Pt B):251\u20139.","journal-title":"Neuropharmacology"},{"key":"573_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550","volume":"186","author":"KO Kopp","year":"2022","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res. 2022;186:106550.","journal-title":"Pharmacol Res"},{"issue":"Suppl 1","key":"573_CR173","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jdi.12464","volume":"7","author":"K Katsurada","year":"2016","unstructured":"Katsurada K, Yada T. Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig. 2016;7(Suppl 1):64\u20139.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"573_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-023-00718-2","volume":"29","author":"X Kang","year":"2023","unstructured":"Kang X, Wang D, Zhang L, Huang T, Liu S, Feng X, et al. Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt\/\u03b2-catenin\/NeuroD1 pathway. Mol Med. 2023;29(1):118.","journal-title":"Mol Med"},{"issue":"3","key":"573_CR175","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jnc.15277","volume":"157","author":"S Tian","year":"2021","unstructured":"Tian S, Tan S, Jia W, Zhao J, Sun X. Activation of Wnt\/\u03b2-catenin signaling restores insulin sensitivity in insulin resistant neurons through transcriptional regulation of IRS-1. J Neurochem. 2021;157(3):467\u201378.","journal-title":"J Neurochem"},{"issue":"5","key":"573_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051725","volume":"21","author":"S Jantrapirom","year":"2020","unstructured":"Jantrapirom S, Nimlamool W, Chattipakorn N, Chattipakorn S, Temviriyanukul P, Inthachat W, et al. Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity. Int J Mol Sci. 2020;21(5):1725.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"573_CR177","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/jnc.13248","volume":"135","author":"DL Ma","year":"2015","unstructured":"Ma DL, Chen FQ, Xu WJ, Yue WZ, Yuan G, Yang Y. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db\/db mice. J Neurochem. 2015;135(2):301\u20138.","journal-title":"J Neurochem"},{"key":"573_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109716","volume":"240","author":"ZJ Wang","year":"2023","unstructured":"Wang ZJ, Li XR, Chai SF, Li WR, Li S, Hou M, et al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway. Neuropharmacology. 2023;240:109716.","journal-title":"Neuropharmacology"},{"issue":"4S_Part_5","key":"573_CR179","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.jalz.2010.05.421","volume":"6","author":"L Li","year":"2010","unstructured":"Li L, Cao D, Lu H, Lewis T, Mans R. O3-05-03: Glucagon-like peptide-1 mimetic peptide Exendin 4 preserves memory function and attenuates neuropathology in APP\/PS1 double transgenic mice. Alzheimers Dement. 2010;6(4S_Part_5):S135.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"573_CR180","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s13311-021-01018-5","volume":"18","author":"LL Bu","year":"2021","unstructured":"Bu LL, Liu YQ, Shen Y, Fan Y, Yu WB, Jiang DL, et al. Neuroprotection of exendin-4 by enhanced autophagy in a parkinsonian rat model of \u03b1-synucleinopathy. Neurotherapeutics. 2021;18(2):962\u201378.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"573_CR181","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/nyas.14791","volume":"1514","author":"J Reiner","year":"2022","unstructured":"Reiner J, Thiery J, Held J, Berlin P, Skarbaliene J, Vollmar B, et al. The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel. Ann N Y Acad Sci. 2022;1514(1):132\u201341.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"573_CR182","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1097\/MIB.0000000000000847","volume":"22","author":"CH Bang-Berthelsen","year":"2016","unstructured":"Bang-Berthelsen CH, Holm TL, Pyke C, Simonsen L, S\u00f8kilde R, Pociot F, et al. GLP-1 induces barrier protective expression in Brunner\u2019s glands and regulates colonic inflammation. Inflamm Bowel Dis. 2016;22(9):2078\u201397.","journal-title":"Inflamm Bowel Dis"},{"key":"573_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175029","volume":"926","author":"Y Su","year":"2022","unstructured":"Su Y, Liu N, Zhang Z, Li H, Ma J, Yuan Y, et al. Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and \u03b1-synuclein accumulation in the colon of two Parkinson\u2019s disease mouse models. Eur J Pharmacol. 2022;926:175029.","journal-title":"Eur J Pharmacol"},{"issue":"10103","key":"573_CR184","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664\u201375.","journal-title":"Lancet"},{"key":"573_CR185","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70760","author":"A Engstr\u00f6m","year":"2026","unstructured":"Engstr\u00f6m A, Svanstr\u00f6m H, Hviid A, Eliasson B, Gudbj\u00f6rnsdottir S, Wintzell V, et al. Use of glucagon-like peptide-1 receptor agonists and risk of Parkinson\u2019s Disease: Scandinavian cohort study. Diabetes Obes Metab.\u00a02026;28(7):5767\u20135778.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"573_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02962-8","volume":"24","author":"M Schechter","year":"2025","unstructured":"Schechter M, Fishkin A, Mosenzon O, Sehtman-Shachar DR, Cukierman-Yaffe T, Leibowitz G, et al. Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study. Cardiovasc Diabetol. 2025;24(1):426.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"573_CR187","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","volume":"32","author":"P Edison","year":"2026","unstructured":"Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, et al. Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial. Nat Med. 2026;32(1):353\u201361.","journal-title":"Nat Med"},{"issue":"8","key":"573_CR188","doi-asserted-by":"publisher","DOI":"10.3390\/nu11081942","volume":"11","author":"W Wang","year":"2019","unstructured":"Wang W, Tanokashira D, Fukui Y, Maruyama M, Kuroiwa C, Saito T, et al. Serine phosphorylation of IRS1 correlates with A\u03b2-unrelated memory deficits and elevation in A\u03b2 level prior to the onset of memory decline in AD. Nutrients. 2019;11(8):1942.","journal-title":"Nutrients"},{"issue":"21","key":"573_CR189","doi-asserted-by":"publisher","first-page":"11588","DOI":"10.3390\/ijms222111588","volume":"22","author":"YK Komleva","year":"2021","unstructured":"Komleva YK, Potapenko IV, Lopatina OL, Gorina YV, Chernykh A, Khilazheva ED, et al. NLRP3 inflammasome blocking as a potential treatment of central insulin resistance in early-stage Alzheimer\u2019s disease. Int J Mol Sci. 2021;22(21):11588.","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"573_CR190","doi-asserted-by":"publisher","DOI":"10.1002\/alz.093368","volume":"20","author":"M Ghuman","year":"2024","unstructured":"Ghuman M, Boutajangout A, Atta A, Kaddioui RE, Kozikowski AP, Wisniewski T. Efficacy of an inhibitor of GSK-3\u03b2 in an Alzheimer\u2019s disease mouse model. Alzheimers Dement. 2024;20(Suppl 1):e093368.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"573_CR191","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/mp.2010.17","volume":"15","author":"KN Manolopoulos","year":"2010","unstructured":"Manolopoulos KN, Klotz LO, Korsten P, Bornstein SR, Barthel A. Linking Alzheimer\u2019s disease to insulin resistance: the FoxO response to oxidative stress. Mol Psychiatry. 2010;15(11):1046\u201352.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"573_CR192","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/0118715273321002240919102841","volume":"24","author":"P Kaur","year":"2025","unstructured":"Kaur P, Khan H, Grewal AK, Dua K, Singh SK, Gupta G, et al. Exploring therapeutic strategies: the relationship between metabolic disorders and FOXO signalling in Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets. 2025;24(3):196\u2013207.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"7","key":"573_CR193","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.2337\/db15-1428","volume":"65","author":"M Sajan","year":"2016","unstructured":"Sajan M, Hansen B, Ivey R 3rd, Sajan J, Ari C, Song S, et al. Brain insulin signaling is increased in insulin-resistant states and decreases in FOXOs and PGC-1\u03b1 and increases in A\u03b21-40\/42 and phospho-tau may abet Alzheimer development. Diabetes. 2016;65(7):1892\u2013903.","journal-title":"Diabetes"},{"key":"573_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2023.111898","volume":"218","author":"T Davidy","year":"2024","unstructured":"Davidy T, Yore I, Cukierman-Yaffe T, Ravona-Springer R, Livny A, Lesman-Segev OH, et al. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- study rationale and design. Mech Ageing Dev. 2024;218:111898.","journal-title":"Mech Ageing Dev"},{"issue":"2","key":"573_CR195","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JPD-191768","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde M, et al. The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson\u2019s disease. J Parkinsons Dis. 2020;10(2):523\u201342.","journal-title":"J Parkinsons Dis"},{"key":"573_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177972","volume":"1003","author":"P Feng","year":"2025","unstructured":"Feng P, Liu Z, Lv D, Hao W, Li D, Xue G, et al. The novel GLP-1 \/ GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson\u2019s disease. Eur J Pharmacol. 2025;1003:177972.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"573_CR197","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40263-025-01226-z","volume":"39","author":"C H\u00f6lscher","year":"2025","unstructured":"H\u00f6lscher C. Incretin hormones GLP-1 and GIP normalize energy utilization and reduce inflammation in the brain in Alzheimer\u2019s Disease and Parkinson\u2019s Disease: from repurposed GLP-1 receptor agonists to novel dual GLP-1\/GIP receptor agonists as potential disease-modifying therapies. CNS Drugs. 2025;39(12):1201\u201320.","journal-title":"CNS Drugs"},{"issue":"3","key":"573_CR198","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3233\/JAD-230593","volume":"96","author":"J Yang","year":"2023","unstructured":"Yang J, Shi X, Wang Y, Ma M, Liu H, Wang J, et al. Multi-target neuroprotection of thiazolidinediones on Alzheimer\u2019s Disease via neuroinflammation and ferroptosis. J Alzheimers Dis. 2023;96(3):927\u201345.","journal-title":"J Alzheimers Dis"},{"issue":"51","key":"573_CR199","doi-asserted-by":"publisher","first-page":"eads5466","DOI":"10.1126\/sciadv.ads5466","volume":"10","author":"CR Reczek","year":"2024","unstructured":"Reczek CR, Chakrabarty RP, D\u2019Alessandro KB, Sebo ZL, Grant RA, Gao P, et al. Metformin targets mitochondrial complex I to lower blood glucose levels. Sci Adv. 2024;10(51):eads5466.","journal-title":"Sci Adv"},{"issue":"1","key":"573_CR200","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05499-9","volume":"63","author":"H Shang","year":"2025","unstructured":"Shang H, Wang Z, Sun Y, Zuo C, Wang M, Zheng K, et al. Metformin inhibits microglial activation-mediated cuproptosis by modulating the TLR4\/Myd88\/NF-\u03baB signaling pathway in Parkinson\u2019s Disease. Mol Neurobiol. 2025;63(1):95.","journal-title":"Mol Neurobiol"},{"issue":"10","key":"573_CR201","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/15384101.2020.1743911","volume":"19","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Bian Y, Zhang Y, Ren G, Li G. Metformin activates AMPK\/SIRT1\/NF-\u03baB pathway and induces mitochondrial dysfunction to drive caspase3\/GSDME-mediated cancer cell pyroptosis. Cell Cycle. 2020;19(10):1089\u2013104.","journal-title":"Cell Cycle"},{"issue":"2","key":"573_CR202","first-page":"182","volume":"32","author":"L Qiu","year":"2016","unstructured":"Qiu L, Jiang X, Wen L, Hu Q, Deng Y. Pioglitazone decreases the levels of inflammatory cytokines in SD rats with traumatic brain injury via up-regulating PPAR\u03b3. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016;32(2):182\u20134.","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"573_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109647","volume":"115","author":"MA Sadek","year":"2023","unstructured":"Sadek MA, Kandil EA, El Sayed NS, Sayed HM, Rabie MA. Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway. Int Immunopharmacol. 2023;115:109647.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"573_CR204","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","volume":"70","author":"MA Reger","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70(6):440\u20138.","journal-title":"Neurology"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-026-00573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-026-00573-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-026-00573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:03:15Z","timestamp":1785783795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40035-026-00573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":204,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1186\/s40035-026-00573-1","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"36"}}